What primary receptor cascades and in vitro signaling axes are modulated by Semaglutide?

Pre-clinical studies indicate Semaglutide engages primary pathways: Potently and selectively activates the human GLP-1 receptor, initiating cellular adenylate cyclase activation. Aib substitution at position 8 confers total resistance against proteolytic degradation by dipeptidyl peptidase-4 (DPP-4). Additional investigations explore cellular migration, receptor binding affinities, and kinase activation in vitro.

What is the recommended reconstitution diluent and sterile handling protocol for Semaglutide?

Lyophilized Semaglutide cakes must be reconstituted using Bacteriostatic 0.9% Benzyl Alcohol USP. Introduce the diluent gently along the internal glass wall under a laminar flow hood, allowing passive dissolution without mechanical vortex shear or high-velocity liquid agitation.

Is Semaglutide lawful to purchase and possess for laboratory research in the United Kingdom?

Yes. Non-scheduled synthetic research peptides like Semaglutide are entirely legal to acquire, import, and hold for bona fide laboratory experimentation in the UK. However, under Regulation 46 of the Human Medicines Regulations 2012 (SI 2012/1916), supply or marketing for human clinical administration without MHRA authorization is strictly unlawful.

UK Academic MonographMetabolic & Incretin SignalingIn Vitro Laboratory Only

Semaglutide

Q: What is the CAS registry number, molecular formula, and mass of Semaglutide?

Semaglutide (Acylated GLP-1 Analogue (31-AA Chain with C18 Diacid Spacer)) is indexed in the CAS Registry under #910463-68-2. Its empirical molecular formula is C187H291N45O59 with a monoisotopic molecular weight of 4113.58 g/mol. It is cataloged under the Metabolic & Incretin Signaling research classification.

Q: What are the storage temperature thresholds and solution kinetics for Semaglutide?

Lyophilized vials require desiccated storage at -20°C desiccated (stable up to 24 months). Once reconstituted into an aqueous solvent, the peptide solution must be stored at 2°C to 8°C refrigerated; do not freeze (stable 30 days) protected from UV degradation. The laboratory stability window is Store away from light; avoid mechanical frothing during dissolution. Avoid repeated freeze-thaw cycles.

Acylated GLP-1 Analogue (31-AA Chain with C18 Diacid Spacer)

PubChem Molecular SpecsValidated

CAS Registry:910463-68-2

Chemical Formula:C187H291N45O59

Monoisotopic MW:4113.58 g/mol

PubChem CID:56843331

Primary Amino Acid Sequence (31 residues)

N-terminus → C-terminus

1His

2Aib

3Glu

4Gly

5Thr

6Phe

7Thr

8Ser

9Asp

10Val

11Ser

12Ser

13Tyr

14Leu

15Glu

16Gly

17Gln

18Ala

19Ala

20Lys(AEEAc-AEEAc-gamma-Glu-17-carboxyheptadecanoyl)

21Glu

22Phe

23Ile

24Ala

25Trp

26Leu

27Val

28Arg

29Gly

30Arg

31Gly

Pre-Clinical Overview

Semaglutide is a synthetic long-acting glucagon-like peptide-1 (GLP-1) receptor agonist modified at position 8 with alpha-aminoisobutyric acid (Aib) and acylated at Lys26 with a C18 fatty diacid chain. Studied in UK endocrinology and metabolic research as a classical mono-incretin reference standard.

Independent Laboratory Audit

Verified UK Suppliers for Semaglutide

5 Audited British & European Sources

Supplier	Assay Purity	Reagent Format	Dispatch Location	Notes
PharmaGrade Store	≥99.2% (HPLC)	vial	United Kingdom (Royal Mail 24)	High-purity lyophilized 5mg vials with verified LC-MS chromatogram and batch purity.
Direct Peptides	≥99.1% (HPLC)	vial	UK Hub & Europe	Research grade lyophilized peptide vials with automated mass spectrometry confirmation.
Direct Sarms	≥98.7% (HPLC)	vial	United Kingdom Express	Analytical reference standard vials tested for GLP-1R affinity assays.
Peptide Works	≥98.9% (HPLC)	vial	Manchester UK Hub	Northern UK laboratory dispatched lyophilized reagent vials with sequence COA.
PharmaLab Global	≥99.4% (HPLC)	pen	London UK Hub	Triple-stage assayed vials and pre-calibrated laboratory multi-dose pen formats.

Biochemical Mechanisms of Action

Molecular Signaling Pathways

1Potently and selectively activates the human GLP-1 receptor, initiating cellular adenylate cyclase activation.
2Aib substitution at position 8 confers total resistance against proteolytic degradation by dipeptidyl peptidase-4 (DPP-4).
3C18 fatty diacid spacer facilitates strong reversible binding to serum albumin, prolonging biological half-life to ~165 hours.
4Suppresses postprandial glucagon secretion and delays gastric motility in isolated physiological models.

Pre-Clinical Laboratory Handling

Laboratory Evaluation Guidelines

Benchmark peptide for incretin-based scientific investigations. Handled with sterile laboratory precautions and maintained refrigerated after reconstitution.

Aseptic Dissolution & StorageUK Lab Standard

Recommended Diluent:Bacteriostatic 0.9% Benzyl Alcohol USP

Lyophilized Storage:-20°C desiccated (stable up to 24 months)

Reconstituted Storage:2°C to 8°C refrigerated; do not freeze (stable 30 days)

Solution Stability:Store away from light; avoid mechanical frothing during dissolution

Academic Biochemical Monograph

Receptor Affinity, SPPS Synthesis & Pharmacokinetics

Standardized chemical parameters, solid-phase synthesis criteria, and quantitative receptor affinity benchmarks for Semaglutide.

Target ReceptorsBinding Kinetics

Primary Receptor Cascade

Glucagon-Like Peptide-1 Receptor (GLP-1R)

Binding Affinity (Kd / Ki)

Ki = 0.38 nM (GLP-1R selective agonist)

Receptor Family

Class B Secretin-like G-Protein Coupled Receptor (GPCR)

Downstream Effectors

cAMP production and PKA activation in pancreatic beta-cells
Inhibition of hepatic gluconeogenesis and fasting glucagon release
Central satiety signaling in hypothalamic POMC neurons

SPPS MethodologyISO Criteria

Synthesis Protocol

Recombinant expression or Fmoc SPPS with AEEA linker and C18 diacid acylation

N-Terminal / C-Terminal Mod

Free amine (H-His-) · Free acid (-Gly-OH)

Acid Cleavage Cocktail

TFA / TIS / H2O (95:2.5:2.5 vol/vol)

HPLC Retention Standard

RP-C18: 17.6 min (0.1% TFA / ACN linear gradient)

PharmacokineticsIn Vitro / In Vivo

Elimination Half-Life

t1/2 ≈ 7 days (165 hours) via C18 diacid spacer albumin anchoring

Primary Degradation Pathway

DPP-4 resistance via Aib8 substitution; cleared via metabolic proteolysis

Bioavailability Profile

Extensively bound to plasma albumin (>99%)

Renal Filtration Threshold

Molecular mass 4,113.58 Da

Quantitative Pre-Clinical & Clinical Evidence Matrix

Documented Biochemical Endpoints & Statistical Significance

Study Design	Cohort (n)	Measured Biological Endpoint	Statistical Significance	NCBI Citation
Double-Blind RCT	n = 1,961 human cohort (STEP-1)	Body mass reduction and cardiometabolic risk profile across 68 weeks	p < 0.001 vs placebo	PMID 33567185
Double-Blind RCT	n = 3,297 human cohort (SUSTAIN-6)	Composite first occurrence of major adverse cardiovascular events	p < 0.001 vs standard care	PMID 27633186

Peer-Reviewed Academic Citations

Indexed Scientific Literature

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

New England Journal of Medicine (2016) · Marso SP, Bain SC, Consoli A, et al.

Key Finding: Documented substantial reductions in cardiovascular death, nonfatal stroke, and myocardial infarction in trial models.

PubMed PMID: 27633186

BIOCHEMICAL & REGULATORY Q&A

Curated Scientific Q&A for Semaglutide

Authoritative pre-clinical, analytical, and statutory handling guidelines for laboratory researchers.

5 Curated Questions

Semaglutide (Acylated GLP-1 Analogue (31-AA Chain with C18 Diacid Spacer)) is indexed in the CAS Registry under #910463-68-2. Its empirical molecular formula is C187H291N45O59 with a monoisotopic molecular weight of 4113.58 g/mol. It is cataloged under the Metabolic & Incretin Signaling research classification.

Citation Benchmark: PubChem CID 56843331; British Pharmacopoeia Appendix III

Biological Pathway Correlates

More Reagents in Metabolic & Incretin Signaling

View Pathway Hub

Mixed Pre-ClinicalCAS 221231-10-3

AOD-9604

Human Growth Hormone C-Terminal Fragment (Tyr-hGH177-191)

C78H123N23O23S21815.12 g/molMetabolic & Incretin Signaling

AOD-9604 is a synthetic hexadecapeptide analog representing the lipolytic C-terminal domain of human growth hormone (hGH 177-191) with an added tyrosine residue. Investigated in UK metabolic and adipose tissue laboratories for beta-3 adrenergic receptor signaling without diabetogenic IGF-1 elevation.

Verified UK Sourcing Partners:

PharmaGrade Store (≥99.1% (HPLC))Direct Peptides (≥99.0% (HPLC))Direct Sarms (≥98.5% (HPLC))Peptide Works (≥98.7% (HPLC))PharmaLab Global (≥99.3% (HPLC))

View Full Technical Monograph

Human Trial DataCAS 2023788-19-2

Tirzepatide

Dual GIP and GLP-1 Receptor Co-Agonist 39-AA Synthetic Peptide

C225H348N48O684813.45 g/molMetabolic & Incretin Signaling

Tirzepatide is a synthetic 39-amino-acid unimolecular dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor co-agonist conjugated to a C20 fatty diacid moiety. Studied extensively in UK biochemical and pharmaceutical research for receptor affinity dynamics.

Verified UK Sourcing Partners:

PharmaGrade Store (≥99.3% (HPLC))Direct Peptides (≥99.2% (HPLC))Direct Sarms (≥98.8% (HPLC))Peptide Works (≥99.0% (HPLC))PharmaLab Global (≥99.5% (HPLC))

View Full Technical Monograph